These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8737121)

  • 1. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
    Baquero F; Cantón R
    J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
    Pechère JC; Gootz TD
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone.
    Iwasaki H; Miyazaki S; Tsuji A; Yamaguchi K; Goto S
    Chemotherapy; 1995; 41(2):100-12. PubMed ID: 7758353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community].
    Prado V; Trucco O; Nina A; Salamanca L; Juliet C; Braun S
    Rev Med Chil; 1995 Nov; 123(11):1394-1401. PubMed ID: 8733283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiology of newer fluoroquinolones: focus on respiratory pathogens.
    Jones RN
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):213-20. PubMed ID: 12493166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections.
    Watanabe A; Tokue Y; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Nukiwa T
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1767-8. PubMed ID: 10390240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
    Crokaert F; Aoun M; Duchateau V; Grenier P; Vandermies A; Klastersky J
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):696-8. PubMed ID: 8894585
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S; Noviello S; Ianniello F
    Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):12S-14S. PubMed ID: 1662881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
    Goa KL; Bryson HM; Markham A
    Drugs; 1997 Apr; 53(4):700-25. PubMed ID: 9098667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance.
    Thornsberry C; Ogilvie PT; Holley HP; Sahm DF
    Clin Ther; 1998; 20(6):1179-90. PubMed ID: 9916611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.
    Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Heifetz CL
    Diagn Microbiol Infect Dis; 1991; 14(5):403-15. PubMed ID: 1665775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
    Richard MP; Aguado AG; Mattina R; Marre R
    J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
    Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
    Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.